Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride

Eggers, Ch.; Rothenberger, Aribert; Berghaus, U.

doi:10.1007/bf00449911

Cited by 101 publications

(52 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, the inclusion of clinically referred children with CTD and=or ADHD limits the generalizability of our findings to epidemiological samples. Second, continuation of antipsychotics in some children during testing might have confounded the results, although e.g., for both tiparide (Rothenberger and Eggers 1982;Eggers et al 1988) and risperidone (Allain et al 2003) there is no evidence of influencing cognitive performance in short-term low-dose medication in healthy volunteers or children with tic disorders. Third, the use of a single clinical measure of color perception (FMT), requiring substantial capacities in sustained attention, should be seen with caution in testing children with ADHD free of stimulant medication.…”

Section: Discussionmentioning

confidence: 99%

Color perception deficits in co-existing attention-deficit/hyperactivity disorder and chronic tic disorders

et al. 2007

Self Cite

View full text Add to dashboard Cite

Summary. Preliminary findings suggest that color perception, particularly of blue-yellow stimuli, is impaired in attention-deficit=hyperactivity disorder (ADHD) as well as in chronic tic disorders (CTD). However, these findings have been not replicated and it is unclear what these deficits mean for the comorbidity of ADHD þ CTD.Four groups (ADHD, CTD, ADHD þ CTD, controls) of children with similar age, IQ and gender distribution were investigated with the Farnsworth-Munsell 100 Hue Test (FMT) and the Stroop-Color-Word Task using a factorial design. Color perception deficits, as indexed by the FMT, were found for both main factors (ADHD and CTD), but there were no interaction effects. A preponderance of deficits on the blue-yellow compared to the red-green axis was detected for ADHD. In the Stroop task only the 'pure' ADHD group showed impairments in interference control and other parameters of Stroop performance. No significant correlations between any FMT parameter and color naming in the Stroop task were found. Basic color perception deficits in both ADHD and CTD could be found. Beyond that, it could be shown that these deficits are additive in the case of comorbidity (ADHD þ CTD). Performance deficits on the Stroop task were present only in the 'pure' ADHD group. Hence, the latter may be compensated in the comorbid group by good prefrontal capabilities of CTD. The influence of color perception deficits on Stroop task performance might be negligible.

show abstract

Section: Discussionmentioning

confidence: 99%

Color perception deficits in co-existing attention-deficit/hyperactivity disorder and chronic tic disorders

et al. 2007

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a placebo-controlled, double-blind, crossover trial, Eggers and colleagues found that tiapride improved tics in children and had no adverse effect on cognitive function [Eggers et al 1988].…”

Section: Other Pharmacological Agentsmentioning

confidence: 99%

Treatment strategies for tics in Tourette syndrome

Eddy

Rickards

Cavanna

2010

Ther Adv Neurol Disord

145

106

View full text Add to dashboard Cite

Tourette syndrome (TS) is a chronic neurodevelopmental disorder characterized by tics: repetitive, involuntary movements and vocalizations. These symptoms can have a significant impact on patients' daily functioning across many domains. Tics tend to be most severe in child and adolescent sufferers, so their presence has the potential to impact a period of life that is both critical for learning and is often associated with the experience of greater social tension and self-consciousness than adulthood. Furthermore, control over tics that lead to physical impairment or self-injurious behaviour is of vital importance in maintaining health and quality of life. There are numerous complicating factors in the prescription of treatment for tics, due to both the side effects associated with alleviating agents and patient characteristics, such as age and comorbid conditions. This review summarizes literature pertaining to the efficacy and safety of both traditionally prescribed and more modern medications. We also discuss the merits of behavioural and surgical techniques and highlight newer emerging treatments. Although treatment response is to some extent variable, there are a number of agents that are clearly useful as first-line treatments for TS. Other interventions may be of most benefit to patients exhibiting refractory tics or more specific symptom profiles.

show abstract

“…69 The specific D2 receptor-blocking agents, tiapride and sulpiride, are commonly used for the treatment of tics in Europe, but they are not available in the United States. 70,71 In doses ranging from 5 to 6 mg/kg body wt/day, tiapride was superior to placebo in decreasing tics after 6 weeks of treatment in 27 children with TS. 70 A retrospective study of sulpiride in 63 patients with TS (age 10 to 68 years) reported a positive response in more than 50% of the sample.…”

mentioning

confidence: 97%

“…70,71 In doses ranging from 5 to 6 mg/kg body wt/day, tiapride was superior to placebo in decreasing tics after 6 weeks of treatment in 27 children with TS. 70 A retrospective study of sulpiride in 63 patients with TS (age 10 to 68 years) reported a positive response in more than 50% of the sample. 71 Because several patients were also receiving other medications for tics, it is difficult to assess the benefits of sulpiride on tics.…”

mentioning

confidence: 97%

Contemporary assessment and pharmacotherapy of Tourette syndrome

Scahill

Erenberg

Berlin

et al. 2006

NeuroRX

271

View full text Add to dashboard Cite

Summary:To develop a guide to clinical assessment and pharmacotherapy for children and adults with Tourette syndrome (TS), we reviewed published literature over the past 25 years to identify original articles and reviews on the assessment and pharmacological treatment of Tourette syndrome, attention-deficit/hyperactivity disorder (ADHD) and obsessivecompulsive disorder (OCD). The literature search also included a survey of reviews published in book chapters. The assessment section was compiled from several reviews. Pharmacological treatments were classified into those with strong empirical support (as evidenced by two positive placebo-controlled studies for tics, OCD, or ADHD in TS samples); modest empirical support (one positive placebo-controlled study), or minimal support (open-label data only). We conclude that accurate diagnosis, including identification of comorbid conditions, is an essential step toward appropriate treatment for patients with TS. In many patients with TS, symptom management requires pharmacotherapy for tics or coexisting conditions. The evidence supporting efficacy and safety for medications used in patients with TS varies. But this evidence offers the best guide to clinical practice.

show abstract

Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride

Cited by 101 publications

References 8 publications

Color perception deficits in co-existing attention-deficit/hyperactivity disorder and chronic tic disorders

Color perception deficits in co-existing attention-deficit/hyperactivity disorder and chronic tic disorders

Treatment strategies for tics in Tourette syndrome

Contemporary assessment and pharmacotherapy of Tourette syndrome

Contact Info

Product

Resources

About